This new extraction method could yield more psilocybin from a single mushroom than previously possible.
Natural psilocybin extraction can have low and unstable yields, which is why many companies opt for synthetic versions. Whenmushroomsare dehydrated, the total psilocybin/psilocin content extracted isthreetimeslowerthanthe total amount believed to be in the mushroom.
Optimi Health (OPTI) developed an extraction technique that not only increases the yield of natural psilocybin, but also protects the compounds from degeneration while reducing the cost of the final drug. On Tuesday, the company announced that it filed a provisional patent application to protect the process.
Along with adding new formulations to the Company’s natural health product portfolio, founder Matthew Bennett to join HAVN Life as Director of Education
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind is pleased to announce that it has completed the acquisition (the “Acquisition”) of patented natural health product formulations that support brain health from Bennett’s Choice (the “Patented Formulations”). The Acquisition will add more products to HAVN Life’s existing line of natural health products, with additional product launches planned in the near future.
“Completing this acquisition is a huge win for HAVN Life, adding a new and excellent set of proprietary formulations to our portfolio of natural health products,” says HAVN Life CEO, Tim Moore. “The fact that Bennett’s Choice products are preferred by professional athletes as part of their brain health recovery lends serious credibility to the efficacy of brain health supplements, and we see great potential for these products to help those in need of brain health support and healing,” he adds.
As part of the deal, Bennett’s Choice founder Matthew Bennett will join the HAVN Life team as Director of Education, lending his expertise and insight to the Company’s efforts to elevate the conversation about brain health and the role of natural health products.
“As an addition to HAVN Life’s existing line of natural health products, the Patented Formulations will be showcased to a broader community, allowing widespread access to products that support brain health and healing,” says Matthew Bennett, HAVN Life’s newly minted Director of Education. “We have seen firsthand the significant positive impact on brain health within our own consumer base and distribution channels. Personally, I am excited to join a very experienced group that is passionate and structured, as they grow the brain health space in a positive and sustainable way,” he adds.
Mr. Bennett’s background as a therapist working with athletes to improve their recovery and performance led him to develop four formulations – Brain Evolve, Brain Beast, Brain Thrive and Brain Dream. Currently, the products are being distributed to 18 professional sports teams, including the Winnipeg Jets®, Manitoba Moose®, Calgary Stampeders®, Washington Wizards®, Houston Texans®, New England Patriots® and Seattle Seahawks®. Performance nutritionists and individual players across the NHL®, NFL®, NBA® and AHL® are using the formulations as part of their player brain health recovery regimen. The product line’s essential blend of natural ingredients is designed to aid sleep, improve energy, and balance mood to help optimize performance, and has been used to support recovery from concussions and brain injury. The products are available through bennettschoice.com and at GNC® locations across Canada, as well as at many Popeyes® supplement stores, at more than 60 Pharmasave® locations, and at a variety of health clinics in Canada and the United States.
On Behalf of The Board of Directors Tim Moore
Chief Executive Officer
About Bennett’s Choice
Matthew Bennett began treating athletes in 2005 as a team athletic therapist, working to improve their recovery and performance. After six seasons working with professional sports teams across the NHL, AHL, CFL and MLB, Bennett opened his own practice in Vancouver, BC, where he continues to work today.
Bennett’s work with professional athletes showed him the impact of concussions and brain health in all aspects of life and led him to research and develop his first formulation, Brain Evolve in the autumn of 2009, which he was able to patent in August of 2015. Brain Evolve is now the only patented treatment for mTBI (concussion) in the USA, with the Canadian patent granted in May 2021. Bennett’s Choice formulations are Health Canada approved and the choice of many professional athletes – now widely available to the consumer market. To find out more about Bennett’s Choice products, visit bennettschoice.com and follow Facebook, Twitter and Instagram for news and updates.
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Preclinical data demonstrated efficacy and an improved safety profile of MSP-4019 and MSP-4020 in head-to-head comparisons against 5-MeO-DMT
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that, in addition to its potential lead new chemical entity (“NCE”) candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020. In preclinical studies, both compounds demonstrated strong efficacy and an improved safety profile in comparison to 5-MeO-DMT and parent compounds.
“Our Family 4 compounds leverage Mindset’s conjugate amplification technology, which has enabled us to rapidly generate clinical candidates that improve upon first-generation psychedelic efficacy and safety. Using a platform approach to advance our differentiated compounds into the clinic, we aim to broaden patient access for mental health sufferers and provide solutions to address a range of patient needs,” said James Lanthier, CEO of Mindset.
“The preclinical results of MSP-4019 and MSP-4020 demonstrated strong efficacy through a mouse head twitch assay and an improved safety profile at a range of doses up to 30 mg/kg,” stated Joseph Araujo, Chief Scientific Officer of Mindset. “Our next generation compounds showed no signs of 5-HT syndrome, a serious potential health risk associated with first-generation drugs, 5-MeO-DMT and DMT. We will continue to validate our novel compounds through translational models as we select one or more lead drug candidates from our Family 4 NCEs to advance into the clinic.”
Mindset’s Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.
To watch a video of Mindset’s CEO discussing the announcement in greater detail, please visit: https://youtu.be/hy-pQlUegP0.
About Mindset Pharma Inc. Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
NBA superstar to speak at Meet Delic in Las Vegas about his embrace of psychedelic treatments and screen the film which chronicles his near-fatal overdose and recovery with psychedelics. He joins world’s leading experts, scientists, and health & wellness advocates to gather for a two-day immersive edutainment experience at AREA15 from November 6 – 7, 2021.
Vancouver, BC, September 28, 2021 –Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on November 7. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers, earning him NBA championships in 2009 and 2010. He joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the goldwinning U.S. men’s basketball team at the 2004 Athens Olympics.
In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwork. Odom’s keynote “Fireside Chat: Lamar Odom & Zappy Zapolin: Reborn” will reunite him with the documentary’s director for an intimate discussion of his healing journey with psychedelic medicine and a preview of the film.
“We’re so honored Lamar will be sharing his personal story of healing with all of us at Meet Delic,” said Jackee Stang, co-founder of Delic. “He has shown tremendous courage facing his past traumas and addiction, and his openness to exploring psychedelic treatments is inspiring. We hope his story will open the hearts and minds of more people so we can truly address the growing mental health crisis we’re facing.”
Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo. The full lineup of keynote speakers and panelists can be found here.
The twenty hours of panels and keynotes will include an array of topics such as “Why Are Psychedelics Medicine?”, “How Big Money is (Already) Playing Psychedelics,” “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “Microdosing,” “Psychedelic Activism,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.
Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.
Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.
About Meet Delic
Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.
About Delic Corp
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information and Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.
By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.
Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.
SOURCE Delic Holdings Inc.
Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com
Media Inquiries: Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com
You’ll want to stay till the end to learn how someone gained a new skill during their first trip!
(Did a good friend forward this to you? If so be sure to subscribe here)
Be sure to check out this week’s Daily Mushroom podcast! Psilocybin, is it the next cannabis wave?
In this episode we have Lenny Kerman, a strategic financial consultant who works with various psilocybin and cannabis companies. He talks about how he’s invested in the space and has some valuable information for those looking to invest as well.
A new study found that combining SSRIs and psilocybin is not only safe, but may be beneficial!
Yesterday, MindMed (MNDM) announced the findings from an ongoing study conducted in collaboration with UHB Liechti Lab.
Psilocybin was found to be safe to administer with an SSRI antidepressant and did not reduce the psychedelic experience. Two weeks prior to the psilocybin dose, volunteers were give a daily pretreatment of the SSRI escitalopram. As a result, the volunteers experienced reduced anxiety and blood pressure increases that can occur with psilocybin administration.
Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.
The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.
The San Diego company just filed an Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.
Mydecine (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.
The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care.
The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).
Mydecine (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.
The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care.
The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).
After half a century, the US federal government has started funding psychedelic research again!
A researcher at Johns Hopkins University received a U01 grant from the National Institute on Drug Abuse (NIDA) to fund a multi-site study on psilocybin for tobacco addiction, which will take place at Johns Hopkins, New York University, and the University of Alabama at Birmingham.
The researcher, Dr. Matthew W. Johnson, noted that this is the first time a psychedelic study has received funding since the War on Drugs was declared in the 70s, marking a “new era in legitimacy of psychedelic science”.
Yesterday, Wake Network Inc. received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for PSIL428, its microdose formulation made from natural psilocybin.
The certification allows the company to run clinical trials on anxiety and depression and makes PSIL429 available to clinics and academic institutions across the globe. Any country with a special access program can request to import the legal formulation for patient use.
In other microdosing news, MindBio Therapeutics, a subsidiary of Blackhawk Growth Corp. (BLR), is partnering with Trip Pharma’s LeichtMind clinic to launch microdosing clinical trials in Canada!
Will psychedelic therapy soon involve vaping shrooms?
Delic (DELC) is the first company to receive Health Canada approval to research psilocybin vaporization.
On Monday, Delic entered into an agreement to acquire Ketamine Wellness Clinics, a company that runs 10 ketamine infusion centers across 8 states. The deal increases Delic’s total number of clinics to 12 and adds over 60 medical professionals to the team, making it the largest psychedelic wellness chain in the US. Within the next 18 months, the company hopes to grow this number to 27 clinics!
Once granted FDA-approval, DELIC aims to offer other psychedelic treatments at these locations including MDMA and psilocybin therapy, which could potentially use the vaporization technology!
MINDCURE’s (MCUR) digital therapeutics platform could improve the psychedelic healing journey for both patients and clinicians!
The software application, iSTRYM, provides clinicians with a global database of therapy protocols, integration plans, and AI-driven data insights into patient journeys. The application connects to mobile and wearable devices to measure patients’ biological response to the treatment, allowing clinicians to provide personalized care. iSTRYM also offers a Mindfulness Suite that patients can use to explore practices like breathwork and meditation to support their healing.
This week, MINDCURE signed into an exclusive licensing agreement with ATMA Journey Centers, a private psychedelic therapy clinic in Calgary, which will grant MINDCURE access to anonymous patient data gathered from ATMA’s use of the platform.
You may want to postpone your trip to Italy till next year 😉
Italian activists collected 500,000 signatures in favour of a referendum to decriminalize marijuana and psilocybin – enough to qualify for a ballot measure!
The referendum would remove Italy’s prohibition on cultivating psychoactive substances, but the further processing required to produce most narcotics would remain illegal. Fortunately, magic mushrooms are ready to enjoy after cultivation alone!
A vote is expected to take place in spring of 2022 given that the Court of Cassation and the Constitutional Court sign off on the measure after reviewing the petition.
Back in May, UK Prime Minister Boris Johnson approved the rescheduling of psilocybin to make it easier to research its therapeutic effects.
Months have passed, yet the Home Office has failed to act, “perpetuating what can be considered the worst research blackout in scientific history,” according to the Conservative Drug Policy Reform Group (CDPRG). Crispin Blunt MP, chairman of the CDPRG, is urging the Home Office to take action fast to tackle the mental health crisis.
A Home Office spokesperson said that there are currently no plans to reschedule psilocybin due to the Misuse of Drugs Regulations 2001, but they will consider any recommendations from The Advisory Council on the Misuse of Drugs (ACMD), which is reviewing the barriers to researching controlled drugs.
Industry Quick Hits
Sept 21 – Eversio Wellness Harvests Its First Legally Grown Psychoactive Mushrooms Read more…
Sept 21 – Clearmind Medicine (CMND) Partners with The Hebrew University to Develop Novel Psychedelic DrugRead more…
This Reddit user gained a new ability during their first trip.
“I’m in my 40s and have been tone deaf as well as having hearing loss my whole life. I can’t carry a tune or recognize notes/melodies, and have never connected emotionally to music. When I dance, I’m just imitating others. I don’t know how to dance to music.
I tried magic mushrooms for the first time. My friend had music playing and at one point during my trip, I started humming and singing. I became the song and my body knew how to dance and play an instrument. My fingers were making the most intricate, precise movements- strumming an instrument like a professional musician. Dance movements came to me and I could feel it in my nervous system as I danced. Afterwards, I was still ready to believe that I was probably horribly out of tune and stumbling around and making stuff up, but my friend- who was not tripping- confirmed that I was carrying a tune, humming the song that was playing, and danced as if I had been trained and done it all my life.
This is just… unbelievable. And also merely a facet of the whole trip! I’d love to hear if this resonates with others and if there have been similar experiences!”
Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience
Thought Leaders, Entrepreneurs, Medical Experts and Entertainment Headliners include Duncan Trussell, Shane Mauss, Alyson Charles, Dr. Carl Hart, Ifetayo Harvey, Aubrey Marcus…and a surprise special guest speaker
Vancouver, BC, September 23, 2021 –Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today released the full lineup of thought leaders, entrepreneurs, medical experts and entertainers taking part in the two-day premier psychedelics event. The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.
The list of thought leaders who will keynote the two-day event taking place from November 6th7th, 2021, at AREA15, an immersive and experiential venue in Las Vegas, includes:
Duncan Trussell, stand-up comedian, podcaster and actor, host of The Duncan Trussell Family Hour
Jason Silva, Venezuelan-American filmmaker, philosopher, television personality, and public speaker
Aubrey Marcus, founder of Onnit, podcast host and best-selling author
Alyson Charles, former TV/radio host and athlete turned author, spiritual teacher, medium and shaman
Dr. Carl Hart, Ziff Professor at Columbia University, former chair of the Department of Psychology and best-selling author
Chris Ryan, PhD, NYT bestselling author and featured speaker at influential conferences such as TED, SXSW, and a frequent guest on The Joe Rogan Experience
Ifetayo Harvey, Founder and board president of the People of Color Psychedelic Collective; activist, writer and social media manager at Caring Across Generations
George Goldsmith, CEO and founder of COMPASS Pathways and an entrepreneur
Ekaterina Malievskaia, MD, Co-founder and Chief Innovation Officer for COMPASS
Luke Storey, Motivational speaker, podcaster, writer, meditation and metaphysics teacher, and lifestyle design expert
Dr. Molly Maloof, Founder of Adamo Bioscience and a lecturer within the Wellness Department of the Medical School at Stanford University
Ben Westhoff, Award-winning investigative reporter who writes about culture, drugs, and poverty
Brittany Hoogenboom, Owner and founder of Synergy Soul, a mind, body, soul, & business brand, and an intuitive business coach
Dr. Dave Rabin,MD, PhD, Neuroscientist, board-certified psychiatrist, health tech entrepreneur and inventor. Co-founder & Chief Innovation Officer at Apollo Neuroscience
Laura Dawn, Msc., Host of The Psychedelic Leadership Podcast, and a microdosing mentor for executives, who has led transformational retreats for over 10 years
Shane Mauss, Stand-up comedian, adventurer, podcaster, psychonaut and science enthusiast
Kyle Bergquist, Founder of Healing Our Heroes, co-founder of Serving Impact, author and documentary filmmaker
Jesse Gould, Psychedelic ranger and founder of Heroic Hearts Project
Zappy Zapolin, Futurist, award-winning filmmaker, and psychedelic concierge to the stars
Clara Burtenshaw, Partner and investor at Neo Kuma Ventures, the first psychedelics focused venture capital fund in Europe
The following business leaders, scientists and health & wellness advocates will come together for a series of thought-provoking panels on making psychedelics accessible to the masses:
Business Panelists
Martin Tobias, Founder of Incisive Ventures, investor and entrepreneur
Matt Stang, Pioneer for the cannabis industry in the U.S. and CEO of Delic Corp
Mark Goldfogel, Serial entrepreneur and co-founder of KERN, the first cannabis compliance company on NASDAQ
Sara Kennedy, Marketing entrepreneur focusing in plant-based particles
Joshua White, Co-founder and Executive Director of Fireside Project
Mitchell Gomez, Executive Director at DanceSafe
Sam Chapman, Executive Director at Healing Advocacy Fund
Dr. Markus Roggen, President and Chief Scientific Officer of Delic Labs
Donald Gauvreau, Founder, CEO and Chairman at Conscious Mind Labs
Ronan Levy, Entrepreneur, founder and Executive Chairman of Field Trip Health
Barbara Branaman, Co-Founder and CEO of BioReset Group, Co-Host of the Clarity Cafe Podcast, doctor of Medical Qigong, yoga and meditation teacher
Paul Rosen, Founder, CEO and Chairman of Tidal Royalty Corporation
Gary Smith, Co-founder and President of Arizona Cannabis Bar Association; author and psychedelic lawyer
Kraig Fox, Advisor and entertainment industry superpower ● Nanea Reeves, CEO and co-founder at TRIPP, Inc.
Sashko Despotovski, Investor and board member at Delic Corp
Dina Burkitbayeva, Founder of PsyMed Ventures, psychedelics biotech investor and entrepreneur
Matt Zemon, Chief Strategy Officer and co-founder at Psychable ● Jennifer Pereira, CEO of Bloom Fund and angel investor
Kathryn Fantauzzi, CEO and co-founder of Apollo Neuroscience
Hanifa Nayo Washington, Sacred activist, co-founder and cultivator of Beloved Community of Fireside Project
Lauren Mendelsohn, Esq., Senior associate attorney, Law Offices of Omar Figueroa
Sonia Weiss Pick, Co-founder and Managing Director at WPSS Investments
Lisa Dannen, MA, Director of Marketing & Communications, Maya Health
Dr. Jeff Chen,MD/MBA, Impact entrepreneur, scientist, and storyteller operating at the convergence of culture, science, and business to heal the body, mind, and planet. Cofounder & CEO of Radical Science
Ifetayo Harvey will also be taking part in a business panel
Wellness Panelists
Adam Bramlage, Founder and CEO ofFlow State, where he works one-on-one with clients to optimize their microdosing experience
Phoebe McPherson, Co-founder of the Hearthstone Collective, a mushroom company on a mission to help others heal with plant medicines
Jemie Sae Koo, CEO of Psychable.com, an online community dedicated to connecting those interested in legally exploring psychedelic-assisted therapy with practitioners who can support them
Victor Mifsud, Creator of the personal feature-length documentary “My Neuroplastic Adventure,” taking viewers from the cutting edge of neuroscience to ancient tribal healing medicines
Dr. Stephanie Coleman, MD/MPH, Holistic and psychedelic medicine physician, educator, and entrepreneur
Dr. Devon Christie, MD, Clinical instructor with the UBC Department of Medicine and has a focused practice in chronic pain management
Will Siu, MD, DPhil, Advisor to Bexson Biomedical and People Science has been trained by MAPS to provide MDMA-assisted therapy
Craig Salerno, LAC/LPC, Licensed addiction counselor and licensed professional counselor
Sashi Gerzon-Rose, LPC, Psychotherapist, yoga and meditation teacher, and ordained monk in the White Plum lineage of Zen Buddhism
David Feifel, MD/PhD, Professor Emeritus of Psychiatry at University of California San Diego and a pioneer in treating mental illness
Spencer Hawkswell, CEO at TheraPsilLobbyist, believes responsible drug policy requires effective organization and leadership
Deanne Adamson, Founder and President of Being True To You and an addiction specialist
Sam Ko, MD/MBA, Founder and Medical Director of Reset Ketamine
Lauren Taus, LCSW, Psychotherapist with a specialty in psychedelic assisted therapies
Amber Amendola, Psychotherapist with 10 years of health and wellness experience, focused on the healing potential of non-ordinary states of consciousness
Robbie Bent, Thought leader in the mental health space building a global community to improve mental health in an accessible way
Dr. Matt Cook, President and founder of BioReset™ Medical and Medical Advisor of Bioreset Network.
Dr. Harry McIlroy,MD, Family physician, licensed acupuncturist, functional medicine practitioner, osteopath, nutritionist, certified Ashtanga yoga teacher
Florencia Bollini, Named “The Corporate Shaman” by Forbes Magazine, one of the pioneering practitioners of the plant medicine world
Dr. Dave Rabin,MD, PhD, Laura Dawn, Msc., Jennifer Pereira and Dr. Jeff Chen,MD/MBA, will also be joining the wellness panels
Entertainment
Attendees will be treated to an exciting mix of live music, visual art and dancers on both evenings.
The greatest hits of psychedelia past, present and future will be played during The Psyche-Delic Experience, an after-party performance on Saturday, November 6, featuring DJ David Starfire and VJ Jonathan Singer, including a tribute to the Legends of psychedelia featuring the music of The Beatles, Jefferson Airplane, Jimi Hendrix, The Grateful Dead with “appearances” by Alan Watts, Timothy Leary, Terrence McKenna and Ram Das
A special tribute performance of Pink Floyd’s “Set The Controls For The Heart Of The Sun” created as a 360 VR immersive film
Futuristic psychedelia dance and techno themes featuring the music of Tipper, Sphongle, Desert Dwellers, Bedouin, and all original music by David Starfire with dancers and performance artists
MINDCHATTER, a project by singer, songwriter, and producer Bryce Connolly, will provide live music on Sunday, November 6. His complex sound displays influences from electronic, indie, singer-songwriter and hip-hop
Dance performances by Little Miss Nasty and visual art by Scott Hedstrom
The twenty hours of panels and keynotes will include an array of topics such as “Psychedelics and the Search for Truth”, “Why Are Psychedelics Medicine?”, “The Shortcomings of Wellness”, “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Psychedelics and Sobriety: The Next Frontier in Recovery“, “Microdosing,” “Psychedelic Activism,” “Digital Dosing: Technology & Innovation Powering Psychedelics”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.
Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.
Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.
###
About Meet Delic
Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.
About Delic Corp
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information and Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.
By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.
Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.
SOURCE Delic Holdings Inc.
Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com
Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com
VANCOUVER, BC, Sept. 23, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licensing agreement with ATMA Journey Centers Inc. (“ATMA”), a pioneer in the psychedelic therapy industry and the first commercial company in Canada to legally treat a palliative patient with psychedelic-assisted therapy using psilocybin. This agreement is an extension to an existing partnership, whereby ATMA will grant MINDCURE an exclusive license to ATMA data from patients using the iSTRYM digital therapeutics software, with the intended goal of further optimizing the platform.
MINDCURE is positioning iSTRYM to be the industry’s distribution network for science-based, evidence-backed protocols and AI (Artificial Intelligence) data systems. iSTRYM is a first-of-its-kind software application that optimizes the healing journey for patients and clinicians — before, during, and after therapy sessions. iSTRYM was built to shift the paradigm of care and access for psychedelic-assisted psychotherapy, reducing the cost of care, improving patient outcomes, and providing a distribution network for psychedelic companies to distribute protocols. As a drug agnostic platform, iSTRYM was built to support not only any type of psychedelic molecule within a treatment protocol, but to support protocols which utilize existing drugs on the market or therapeutic protocols that might not need a drug at all, as in traditional talk therapy.
MINDCURE plans initially to service psychedelic clinics and to expand into integrated clinics, both traditional and psychedelic, and eventually to the broader mental health market. In August, the Company released the minimum viable product (MVP) version of iSTRYM into partner clinics across North America. MINDCURE plans to begin full commercial deployment in Q1 of 2022.
“We are thrilled to expand our collaboration with the team at ATMA. With data being a core component to refining iSTRYM, having access to ATMA’s network of therapists and anonymized patient data will improve our ability to provide the tools, protocols, and treatments to therapists, and enable us to address a global mental health crisis in need of a solution,” said Kelsey Ramsden, MINDCURE President and CEO. “ATMA’s growing clinical footprint in Canada along with its recently inaugurated center in Costa Rica gives MINDCURE the opportunity to deploy iSTRYM, with the intended goal of optimizing treatments for its patients and to expose iSTRYM to the data necessary to build the platform into one trusted by therapists and patients around the world.”
“Our partnership with ATMA is an exciting opportunity for MINDCURE to demonstrate the effectiveness of iSTRYM’s treatment protocols and to identify those treatment components that are associated with optimal client outcomes. This is at the core of what we have built iSTRYM to do,” said Ty Tashiro, MINDCURE Senior Translational & Psychometric Architect. “This particular collaboration will allow us to deploy iSTRYM’s multifaceted assessment capabilities, including biometrics, natural language processing and unique psychometrics, to create a responsive, personalized treatment experience.”
“We look forward to helping MINDCURE develop iSTRYM into the leading digital therapeutics platform for therapists conducting psychedelic-assisted psychotherapy,” said David Harder, Co-CEO and Co-Founder of ATMA. “Real data from patients will further strengthen and improve the protocols we use and the effectiveness of treatments we deliver at our Journey Centers.”
In related news, MINDCURE successfully launched the minimum viable product (MVP) of iSTRYM on August 26, 2021. The Company is on track to expand into over ten clinics across Canada and the U.S. within the MVP beta testing program in Q4 2021.
About Mind Cure Health Inc. MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.
About ATMA Journey Centers Inc. ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. A pioneer in the psychedelic therapy industry, ATMA is building a global network of psychedelic therapy clinics. ATMA was the first private sector service provider in Canada to announce conducting legal psychedelic-assisted therapy for a palliative care patient under the approval of Health Canada’s section 56(1) exemption. Its team collectively has over 100 years of experience in the disciplines of medicine work, integration, therapy and personal development.
On Behalf of the Board of Directors Kelsey Ramsden, President & CEO Phone: 1-888-593-8995
Forward-Looking Information Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated; or that ATMA’s anonymized patient data will further optimize the iSTRYM platform or will improve MINDCURE’s ability to provide the tools, protocols, and treatments to therapists.
Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
SOURCE Mind Cure Health Inc.
For further information: MINDCURE Investor Relations: investors@mindcure.com, 1-888-593-8995; Media Inquiries: Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com
MINDCURE’s (MCUR) digital therapeutics platform could improve the psychedelic healing journey for both patients and clinicians!
The software application, iSTRYM, provides clinicians with a global database of therapy protocols, integration plans, and AI-driven data insights into patient journeys. The application connects to mobile and wearable devices to measure pateints’ biological response to the treatment, allowing clinicians to provide personalized care. iSTRYM also offers a Mindfulness Suite that patients can use to explore practices like breathwork and meditation to support their healing.
This week, MINDCURE signed into an exclusive licensing agreement with ATMA Journey Centers, a private psychedelic therapy clinic in Calgary, which will grant MINDCURE access to anonymous patient data gathered from ATMA’s use of the platform.
TORONTO, Sept. 23, 2021 (GLOBE NEWSWIRE) —Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs, today announced that it has been included in the AdvisorShares Psychedelics ETF traded on the NYSE Arca under the ticker symbol “PSIL.”
PSIL is an actively managed exchange-traded product that invests in the emerging psychedelic drugs sector. The PSIL offers exposure to biotechnology, pharmaceutical and life sciences companies deriving the majority of their net revenue or devoting the majority of their assets to psychedelic drugs, and only holds companies that they see as leading the way in this industry.
“Mindset’s inclusion in the actively-managed PSIL is another positive step in building awareness and education for the exciting developments at Mindset, as well as the psychedelics industry as a whole. We are thrilled to be considered a leader in the space and appreciate the support from the capital markets as we progress our differentiated pipeline of next generation psychedelic-inspired drug candidates towards the clinic,” said James Lanthier, Chief Executive Officer of Mindset.
About Mindset Pharma Inc. Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
VANCOUVER, BC, Sept. 22, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research in psychedelics, announced today it has been included in the new AdvisorShares Psychedelics ETF, trading on the NYSE Arca under the ticker symbol “PSIL” (the “ETF”).
PSIL offers exposure to biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry. The ETF is actively managed and concentrates its investments in companies receiving the majority of their net revenue or allocating the majority of their assets from psychedelic drugs.
Kelsey Ramsden, MINDCURE President and CEO, said: “MINDCURE’s inclusion in the AdvisorShares Psychedelics ETF is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity. MINDCURE is proud to be acknowledged as a leader in this emerging space and our inclusion in the ETF will increase investor awareness to the Company and the benefits of psychedelic treatment methods to improve mental health.”
You can find additional information on the AdvisorShares Psychedelics ETF here.
About Mind Cure Health Inc. MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook,Twitter, andInstagram.
On Behalf of the Board of Directors Kelsey Ramsden, President & CEO Phone: 1-888-593-8995
Forward-Looking Information Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.
Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
SOURCE Mind Cure Health Inc.
For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Media Inquiries, Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
